UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 85.6%

Neg 0% Neu 0% Pos 85.6%

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $36 to $42.